NASDAQ NMS - GLOBAL MARKET · ENSC
-3.90% · -$0.0108 · Vol 440.2K
Market closed · last close 4:00 PM ET · price as of 19:48:02 ET
Ensysce Biosciences Inc

Ensysce Biosciences Inc

Biotechnology
$0.2662
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
HISTORY WINDOW BUILDING
AI Analysis
Sovereign

Why is ENSC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for ENSC are being assembled.
About Ensysce Biosciences Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
10
Country
US

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.2716
Day high
$0.2839
Day low
$0.2642
Previous close
$0.2770
52W high
$0.2839
-6.23% from high
52W low
$0.2642
10% of range
Market cap
$4.3M
EPS
$-3.1300
Shares out
15.4M
Volume
440.2K
VWAP
$0.2706
Price history computed in-house
SMA 50 $0.2666 · below
SMA 200 $0.2666 · below
52W position 10%
Veridion warehouse edge

Warehouse intelligence for ENSC.

Veridion Score
66
0: 951: 312: 253: 754: 795: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ENSC insider activity

Ensysce Biosciences Inc

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for ENSC.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ENSC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ENSC in this window.
Lobbying spend

ENSC lobbying filings, year to date.

Registered lobbying filings matched to Ensysce Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ENSC in this window.
Latest news · ENSC
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ENSC.
Options
Sovereign unlock shows live options positioning for ENSC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.